Status: Not yet recruiting
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events
This is a randomized, double-blind, placebo-controlled Phase II trial evaluating the efficacy and safety of oral SAL0137 in adults with elevated Lp(a) and high cardiovascular risk. Participants will be randomized 1:1:1:1 to receive low-dose SAL0137, medium-dose SAL0137, high-dose SAL0137, or placebo for a treatment period of 12 weeks. The study assesses changes in Lp(a) levels and safety parameters.
Participants needed: 120
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.Updated: Jul 27, 2026Locations: 1
Eligibility criteria
Aged ≥ 18 years on the date of signing the informed consent form, male or female... [+7]
Experienced any of the following within 3 months prior to screening or prior to... [+22]